An observational study in IgG4-related Disease, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-04-11.
Sponsored by Peking Union Medical College Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital — 7 open to participants now, 7 under way, 1 of them phase 3. Immunoglobulin G4-Related Disease · Peking Union Medical College Hospital.
Among the 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital, this one is one of 3 that started in 2012, is one of 4 observational ones, and was the 2nd registered.
73 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.
Browse Immunoglobulin G4-Related Disease studies →7 of the 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital are open now, in 1 country. Recruiting first, the newest first:
Peking Union Medical College Hospital · Sites in China
Ages 18–75
Peking Union Medical College Hospital · Sites in China
Ages 18–75
Peking Union Medical College Hospital · Sites in China
Ages 18–75
Peking Union Medical College Hospital · Sites in China
Peking Union Medical College Hospital
Ages 18+
By country, each count listing its studies:
Of the 27 Immunoglobulin G4-Related Disease studies recruiting now, 11 (41%) set no upper age limit and 13 (48%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 2 · Phase 4 1
First in 2012; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 112 across 20 observational studies indexed under Immunoglobulin G4-Related Disease.
Median enrollment 74 across the 11 interventional studies, 780 across the 4 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Peking Union Medical College Hospital is the lead sponsor of 1,158 studies on the registry; 477 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
1 of the studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03023371Peking Union Medical College HospitalNational Registry of IgG4-RD in China | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an cohort study to investigate the disease course and treatment response of patients with IgG4-related disease.
Immunoglobulin G4-related disease (IgG4-RD) is a recently defined emerging clinical entity characterized by tissue infiltration by IgG4-positive plasma cells, tissue fibrosclerosis and elevated serum IgG4 concentration.
In this study, patients with IgG4-RD will be investigated, including clinical presentation, laboratory findings and imaging study. All patients will be treated by standard care and follow-uped for at least 6 months.
Adult patients with newly diagnosed IgG4-related disease.
Inclusion Criteria:
Patients with IgG4-RD:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with IgG4-RD, including sclerosing pancreatitis, sclerosing cholangitis, inflammatory pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial nephritis, hypophysitis, sclerosing dacryoadenitis, sialadenitis (Mikulicz disease and Küttner's tumor), inflammatory aortic aneurysm, lymphadenopathy, or other inflammatory conditions.
Clinical Response
Clinical Response is measured by IgG4-RD Responder Index, including organ/site score and serum IgG4 level.
Time frame: 6 months
Started Jan 2012 (actual). Primary completion is estimated for Jan 2032, 240 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Immunoglobulin G4-Related Disease →
Peking Union Medical College Hospital →